Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4266-4274

  Carloni, Vinicio ^a   Vizzutti, Francesco ^a   Pantaleo, Pietro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 (4 CYANOPHENYL) 2 HYDROXY 2 (1 METHYL 1H IMIDAZOL 5 YL)ETHOXY] 4' (TRIFLUOROMETHOXY) 1,1' BIPHENYL 3 CARBONITRILE; ABT 100; CARCINOGEN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAS PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CANCER; LIVER CARCINOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; RNA SEQUENCE; TUMOR VOLUME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALKYL AND ARYL TRANSFERASES; ANIMALS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAP1 GTP-BINDING PROTEINS; RAS PROTEINS; RATS; RATS, WISTAR;

EID: 20344404979     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2386     Document Type: Article

References (41)

1. Llovet MJ, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
2. Carloni V, Mazzocca A, Ravichandran SK. Tetraspanin CD81 is linked to ERK/MAP kinase signaling by Shc in liver tumor cells. Oncogene 2004;23:1566-74.
3. Carloni V, Mazzocca A, Pantaleo P, Cordelia C, Laffi G, Gentilini P. The integrin α6β1 is necessary for the matrix-dependent activation of FAK and MAPkinase and the migration of human hepatocellular carcinoma cells. Hepatology 2001;34:42-9.
4. Carloni V, Romanelli RG, Mercurio AM, et al. Knockout of α6β1 integrin expression reverses the transformed phenotype of hepatocellular carcinoma cells. Gastroenterology 1998;115:433-42.
5. Hong WK, Sporn MB. Recent advance in chemoprevention of cancer. Science 1997;278:1073-7.
6. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
7. Mazzocca A, Giusti S, Hamilton DA, Sebti MS, Pantaleo P, Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Mol Pharmacol 2003;63: 159-66.
8. Gunning TW, Kramer MP, Lubet AR, et al. Chemoprevention of Benzopyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. Clin Cancer Res 2003;9:1927-30.
9. Zhang Z, Wang Y, Lantry EL, et al. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene 2003;22:6257-65.
10. Mangues R, Corral T, Kohl NE, et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-Ras in transgenic mice. Cancer Res 1998;58:1253-9.
11. Du Wei, Liu A, Prendergast GC. Activation of the PI-3K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 1999;59: 4208-12.
12. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001;98: 10983-5.
13. KIP1. Mol Cell Biol 1997;17:3850-7.
14. Kip1. Nature 2000;404:782-7.
15. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-44.
16. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
17. Graveel RC, Jatkoe T, Madore JS, Holt LA, Farnham JP. Expression profiling and identification of novel genes in hepatocellular carcinoma. Oncogene 2001; 20:2704-12.
18. Burr WA, Hillan JK, McLaughlin KE, et al. Hepatocyte growth factor levels in liver and serum increase during chemical hepatocarcinogenesis. Hepatology 1996;24:1282-7.
19. Pilot HC. Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 1990;30:465-500.
20. Ferguson D, Rodriguez LE, Raima JP, et al. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by anti-proliferative, pro-apoptotic and anti-angiogenic effects in xenograft models. Clin Cancer Res 2005;11:3045-54.
21. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274:36031-4.
22. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
23. Lloyd RV, Erickson AL, Jin L, et al. p27KIP1 a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-23.
24. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27 is haplo-insufficient for tumour suppression. Nature 1998;396:177-80.
25. Tannapfel A, Grund D, Katalinic A, et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer 2000;89:350-5.
26. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barren's associated adenocarcinoma. Cancer Res 1998;58:1730-5.
27. Fiorentino M, Altimari A, D'Errico A, et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000;6:3966-72.
28. van Weering JHD, de Rooij J, Marte B, Downward J, Bos LJ, Burgering MTB. Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase mediated events differentially regulated by endogenous Ras. Mol Cell Biol 1998;18: 1802-11.
29. Lerner EC, Qian Y, Blaskovich MA, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signalling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995; 270:26802-6.
30. Hancock FJ. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003;4: 373-84.
31. Prior IA, Hancock JF. Compartmentalization of Ras proteins. J Cell Sci 2001;114:1603-8.
32. Kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH3T3 fibroblasts. Mol Cell Biol 1997;17:5348-58.
33. KIP1 safeguards against inflammatory injury. Nat Med 1998;4:575-80.
34. Kip1. J Biol Chem 2000;275:21960-8.
35. Brazil PD, Yang Z-Z, Hemmings AB. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-42.
36. 2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci U S A 1992;89: 2824-8.
37. Guadagno TM, Newport JW. CDK2 kinase is required for entry into mitosis as positive regulator of Cdc2-cyclin B kinase activity. Cell 1996;84:73-82.
38. 2 phase roles for CDK2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001;21:2755-66.
39. KIP1 of cyclin-dependent kinase 4 activation. Cell 1994;79:487-96.
40. Kip1, a cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 2000;274:37-42.
41. 1 arrest. Mol Cell Biol 2002;22: 2993-3002.